Short Interest in Evox Therapeutics plc (NASDAQ:EVOXW) Declines By 87.3%

Evox Therapeutics plc (NASDAQ:EVOXW) saw a significant decline in short interest during the month of April. As of April 30th, there was short interest totaling 10,272 shares, a decline of 87.3% from the April 15th total of 80,904 shares. Based on an average trading volume of 3,013 shares, the short-interest ratio is presently 3.4 days.

Evox Therapeutics Price Performance

Shares of EVOXW traded down $0.01 during mid-day trading on Tuesday, reaching $0.36. 2,500 shares of the company’s stock were exchanged, compared to its average volume of 44,108. Evox Therapeutics has a 52-week low of $0.30 and a 52-week high of $0.62. The stock’s 50-day simple moving average is $0.41.

Evox Therapeutics plc is a biotechnology company developing therapeutics built on engineered extracellular vesicles (EVs), commonly referred to as exosomes, designed to deliver a broad range of therapeutic payloads. The company’s platform focuses on using naturally occurring nanoscale vesicles as vehicles to carry biologics—such as RNA, proteins and other macromolecules—into target cells and tissues. Evox aims to leverage the innate properties of EVs for targeted delivery, biodistribution and reduced immunogenicity compared with some synthetic delivery systems.

The company’s research and development activities center on engineering EVs for tissue-specific targeting and intracellular delivery, with the goal of addressing diseases that are difficult to treat with conventional approaches, including disorders of the central nervous system and certain rare genetic conditions.